A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy, safety and tolerability of monthly
intravenous Mircera for the maintenance of hemoglobin levels in dialysis patients with
chronic renal disease, currently receiving epoetin alfa or beta. Patients will receive
monthly intravenous injections of Mircera at a starting dose of 120, 200 or 360
micrograms/month, depending on the dose of epoetin alfa or beta they were receiving in the
week preceding study start. The anticipated time on study treatment is 3-12 months, and the
target sample size is 100-500 individuals.